Summary

Overview
Global Clot Management Devices Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.
Clot management devices are intended to prevent, identify, and treat problems linked to blood clots. Deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis are among the disorders that these devices are used to treat. Blood clots in blood arteries are mechanically removed using thrombectomy devices. These tools can be applied to the legs, lungs, and brain, among other body areas. Mechanical thrombectomy tools and aspiration catheters are two examples.
Catheter-Directed Catheters are used in thrombolysis devices to deliver thrombolytic drugs directly to the clot. These drugs aid in dissolving the clot and resuming blood flow. DVT, PE, and other diseases are frequently treated with catheter-directed thrombolysis. The prevalence of vascular diseases such as arterial thrombosis, pulmonary embolism, and deep vein thrombosis is on the rise, which has boosted the demand for clot management devices.
The development of more efficient and minimally invasive clot management tools has been made possible by ongoing developments in medical technology, improving patient outcomes and speeding up recovery.
Dynamics
FDA Approvals
For instance, in January 2023, Penumbra, Inc., a worldwide healthcare firm focused on cutting-edge medicines reported that the most sophisticated and potent mechanical thrombectomy system on the market, Lightning Flash, has been approved for use by the U.S. Food and Drug Administration (FDA). Penumbra's innovative Lightning Intelligent Aspiration technology with twin clot detection algorithms, is featured in Lightning Flash. Lightning Flash is intended to quickly remove big blood clots from the body, such as venous thrombus and pulmonary emboli (PE), in conjunction with cutting-edge catheter engineering.
The Penumbra ENGINE-powered Lightning Flash uses pressure- and flow-based algorithms to identify blood clots and blood flow. The MaxID hypotube technology used to create the Lightning Flash catheter allows for an inner diameter that is comparable to large-bore catheters while keeping a low profile and a soft, atraumatic tip intended to aid in navigating the intricate and delicate structure of the body. The device's combined use is meant to facilitate fast blood clot removal while limiting potential blood loss.
Active Major Players
In March 2023, in some domestic Indian regions, SMT stated that it had been chosen as the sole distributor of Penumbra's peripheral and coronary vascular thrombectomy technology. In accordance with the terms of the contract, SMT will offer healthcare providers Penumbra's most recent Indigo System portfolio, including CATTM RX, which recently received approval from India's Central Drug Standard Control Organization, and Lightning technologies, upon regulatory approval, to treat conditions like coronary thrombosis, venous thrombosis, arterial thrombosis, and pulmonary embolism.
With Lightning Aspiration Tubing, Penumbra's Indigo System portfolio is the first and only computer-aided mechanical aspiration technology that can distinguish between clot and blood, reducing blood loss. It is designed for single-session blood clot removal in peripheral arterial and venous systems, including the treatment of pulmonary embolism. Additionally, Penumbra's Indigo System CAT RX is made to remove blood clots from the coronary and peripheral arteries safely and effectively.
Increasing Collaboration Among Key Players
In June 2023, Sensome, a leader in the field of smart medical devices, and Asahi Intecc, a global leader in the guidewire industry, joined forces to create the next-generation Clotild Smart Guidewire. Asahi Intecc will be responsible for manufacturing this ground-breaking device for the treatment of acute ischemic stroke.
The most common cause of acquired long-term disability is a cerebral ischemic stroke, which is treatable with a treatment called mechanical thrombectomy. This procedure uses a thrombectomy tool that is guided along a wire from the wrist or groin to the blockage site to remove a clot that is clogging a blood artery in the brain. Rapid clot removal with little effort significantly improves patient outcomes.
Increasing Prevalence of Cardiovascular Diseases
According to the World Health Organization, with 17.9 million deaths per year, cardiovascular diseases (CVDs) are the leading cause of death worldwide. Coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other illnesses are among the categories of heart and blood vessel disorders known as CVDs. Heart attacks and strokes account for more than four out of every five CVD deaths, and one-third of these deaths happen before the age of 70.
According to a study that was published in the Journal of the American College of Cardiology, the estimated rates of cardiovascular risk factors and disease will considerably rise in the United States by the year 2060. Significant rises in cardiovascular trends could place a greater strain on the American healthcare system and underscore the need for fair access to early disease preventive services including education and treatment.
High Cost of Devices
In-depth engineering, research, and clinical testing are all necessary for the creation of new medical devices, and they all add to the overall price of bringing a product to market. Manufacturers must spend money on thorough testing and paperwork in order to comply with severe regulatory criteria for safety and efficacy, which raises the cost.
Specialized materials that adhere to strict requirements for sterility, durability, and biocompatibility are frequently needed for medical devices. The cost of obtaining and processing these resources can be high. Complex manufacturing procedures, trained personnel, and quality control procedures may be needed to produce intricate medical devices with cutting-edge technology.
Technical Challenges
Technical difficulties in ensuring that all components perform properly together can arise when creating medical devices with complex designs and functionalities. It can be difficult to ensure compatibility with current medical tools, practices, and workflows, particularly when incorporating new devices into mature infrastructures.
For devices to be used safely and effectively, user-friendly, intuitive interfaces for healthcare workers must be designed. Complex circulatory systems must be navigated with catheters while limiting injury to the surrounding tissues, which calls for expertise and high-tech imaging guidance.
Segment Analysis
The global clot management devices market is segmented based on type, end-user and region.
Catheter Directed Thrombolysis Devices Dominate the Market
Deep vein thrombosis (DVT) or pulmonary embolism are two conditions in which blood clots (thrombi) are clogging blood vessels in the legs. Catheter-directed thrombolysis (CDT) is a medical procedure used to treat both conditions. A small, flexible tube called a catheter is placed into the damaged blood artery. Typically, a small incision is used, and imaging methods like fluoroscopy or ultrasound are used to direct the catheter to the clot's location.
A thrombolytic agent, commonly referred to as a clot-dissolving medicine, is administered directly into the clot through the catheter. By dissolving the fibrin strands holding the clot together, thrombolytics enable the body's clot-dissolving systems to clear the impediment. Depending on the size and location of the clot, the length of time the drug is administered can change. The clot is intended to gradually dissolve, allowing blood flow to return. The remnants of the disintegrated clot may occasionally be naturally removed by blood flow. In other situations, the catheter could be utilized to manually or suctionally remove the clot fragments.
Geographical Penetration
Advanced Healthcare Infrastructure, Increased Cardiovascular Disease
North America has been a dominant force in the global clot management devices market. Pulmonary embolism (PE) is a major cause of illness burden. PE is the third biggest cause of cardiovascular disease-related death in the United States, where it is expected to cause 100,000 fatalities annually.
There is growing evidence that prompt and thorough thrombus removal in deep vein thrombosis leads to better results, such as a lower incidence of post-thrombotic syndrome and incapacitating long-term symptoms. Catheter-directed thrombolysis works well to remove clots quickly, however, treatment comes with a high risk of bleeding. Without the need for systemic or catheter-directed thrombolytic therapy, percutaneous mechanical thrombectomy is a very efficient way to remove clots.
For instance, Edwards Lifesciences Corporation offers the Fogarty graft thrombectomy catheter. AV fistulas for dialysis access and grafts for iliofemoral bypass are two examples of synthetic bypass grafts that are intended to be cleaned of organized thrombus and adhering thrombotic debris. They provide a wider range of diameters than the Fogarty adherent clot catheter, which is useful for a thrombus that is too resistant for an elastomeric balloon.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global clot management devices market. Many healthcare systems reallocated resources to deal with COVID-19 cases at the height of the pandemic. Non-urgent medical operations, such as those involving clot management, were consequently delayed.
The management of COVID-19 patients took over hospitals' and healthcare facilities' attention, which had an impact on the resources available for treating other medical disorders. Patient visits to healthcare facilities for conditions unrelated to COVID-19 decreased because of lockdowns, limits on movement, and patient fears of getting the virus.
Russia-Ukraine War Impact Analysis
Healthcare systems may be under pressure by armed situations that take resources and focus away from treatments involving clot management devices. The violence may interrupt supply lines for medical equipment and supplies, which could influence the accessibility of clot control devices.
Patients' ability to reach medical facilities and receive timely clot management therapies is hampered by the conflict. Elective procedures like clot management interventions are delayed if healthcare facilities prioritize urgent cases over non-urgent ones.
By Type
• Embolectomy Balloon Catheter
• Catheter Directed Thrombolysis Devices
• Percutaneous Thrombectomy Devices
• Inferior Vena cava Filters
• Neurovascular Embolectomy Devices
• Others
By End-users
• Hospitals
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In August 2022, Inari Medical announced a trial for the ClotTriever system to treat iliofemoral deep vein thrombosis (DVT).
Competitive Landscape
The major global players in the market include Medtronic Plc, Boston Scientific Corporation, Edward Lifesciences, Teleflex Incorporated, Johnson & Johnson, LeMaitre Vascular, Inc., AngioDynamics, iVascular SLU, Cardinal Health, and Stryker.
Why Purchase the Report?
• To visualize the global clot management devices market segmentation based on product, end-users, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of clot management devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global clot management devices market report would provide approximately 61 tables, 58 figures, and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents